Literature DB >> 24472228

Supplementation of oil-based inactivated H9N2 vaccine with M2e antigen enhances resistance against heterologous H9N2 avian influenza virus infection.

Jae-Keun Park1, Dong-Hun Lee1, Chung Hwan Cho2, Seong-Su Yuk1, Erdene-Ochir To1, Jung-Hoon Kwon1, Jin-Yong Noh1, Byoung-Yoon Kim1, Soo-Won Choi1, Byoung-Shik Shim2, Man Ki Song2, Joong-Bok Lee1, Seung-Yong Park1, In-Soo Choi1, Chang-Seon Song3.   

Abstract

Avian influenza virus (AIV) subtype H9N2 has been evolving rapidly and vaccine escape variants have been reported to cause circulation of infections and economic losses. In the present study, we developed and evaluated ectodomain of the AIV matrix 2 (M2e) protein as a supplementing antigen for oil-based inactivated H9N2 vaccine to increase resistance against vaccine escape variants. AIV H9N2 M2e antigen was expressed in Escherichia coli and supplemented to inactivated H9N2 oil emulsion vaccine. Specific pathogen-free chickens received a single injection of inactivated H9N2 oil emulsion vaccines with or without M2e supplementation. At three weeks post vaccination, hemagglutination inhibition tests and enzyme-linked immunosorbent assays were performed to determine serological immune responses. Challenge study using a vaccine escape H9N2 variant was performed to evaluate the efficacy of M2e supplementation. M2e antigen supplemented in oil emulsion vaccine was highly immunogenic, and a single M2e-supplemented vaccination reduced challenge virus replication and shedding more effectively than non-supplemented vaccination.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Avian influenza; Chicken; H9N2; M2e; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24472228     DOI: 10.1016/j.vetmic.2014.01.001

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  Antigenic evolution of H9N2 chicken influenza viruses isolated in China during 2009-2013 and selection of a candidate vaccine strain with broad cross-reactivity.

Authors:  Yandi Wei; Guanlong Xu; Guozhong Zhang; Chu Wen; Furkat Anwar; Shuoguo Wang; Gordon Lemmon; Jinliang Wang; Robert Carter; Min Wang; Honglei Sun; Yipeng Sun; Jixun Zhao; Gang Wu; Robert G Webster; Jinhua Liu; Juan Pu
Journal:  Vet Microbiol       Date:  2015-11-02       Impact factor: 3.293

2.  Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.

Authors:  Byung-Min Song; Hyun-Mi Kang; Eun-Kyoung Lee; Suk Chan Jung; Min-Chul Kim; Yu-Na Lee; Sang-Moo Kang; Youn-Jeong Lee
Journal:  Vaccine       Date:  2015-12-12       Impact factor: 3.641

3.  Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; Jongsang Lee; Cheol Kim; Suk-Hoon Ha; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2015-08-04       Impact factor: 5.970

4.  A novel M2e-multiple antigenic peptide providing heterologous protection in mice.

Authors:  Feng Wen; Ji-Hong Ma; Hai Yu; Fu-Ru Yang; Meng Huang; Yan-Jun Zhou; Ze-Jun Li; Xiu-Hui Wang; Guo-Xin Li; Yi-Feng Jiang; Wu Tong; Guang-Zhi Tong
Journal:  J Vet Sci       Date:  2016-03-22       Impact factor: 1.672

5.  Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens.

Authors:  Mohamed Elaish; John M Ngunjiri; Ahmed Ali; Ming Xia; Mahmoud Ibrahim; Hyesun Jang; Jagadish Hiremath; Santosh Dhakal; Yosra A Helmy; Xi Jiang; Gourapura J Renukaradhya; Chang-Won Lee
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

6.  Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Sang-Moo Kang
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.